Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of GL-V9 and anthracycline antibiotics in preparation of leukemia treatment medicine

A technology of GL-V9 and therapeutic drugs, applied in the field of medicine, can solve the problems such as the combined application of GL-V9 in the treatment of leukemia that has not yet occurred

Pending Publication Date: 2021-06-04
CHINA PHARM UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, the main treatments for leukemia include chemotherapy, radiotherapy, immunotherapy, hematopoietic stem cell transplantation, etc., and there is no report on the combined application of GL-V9 and other drugs in the treatment of leukemia.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of GL-V9 and anthracycline antibiotics in preparation of leukemia treatment medicine
  • Application of GL-V9 and anthracycline antibiotics in preparation of leukemia treatment medicine
  • Application of GL-V9 and anthracycline antibiotics in preparation of leukemia treatment medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Effects of GL-V9 combined with daunorubicin on the growth of human AML cells

[0022] 1. Reagents

[0023] (1)GL-V9(C 24 h 27 o 5 N, molecular weight: 409.47) provided by China Pharmaceutical University, light yellow powder, purity greater than 99%, the drug powder is prepared into 0.02M mother solution with dimethyl sulfoxide (DMSO) before use, and stored at -20°C. Daunorubicin injection was provided by Nanjing Drum Tower Hospital and kept away from light. All the reagents were mixed with RPMI-1640 culture medium containing 10% fetal bovine serum to make up the required concentration before use.

[0024] (2) Cell culture reagents

[0025] ①Culture medium: RPMI-1640 medium, purchased from GIBCO, USA. Take 10.39g of RPMI-1640 powder and dissolve it in 1000mL sterile three-distilled water, and add 2.0g NaHCO 3 , adjust the pH value to 7.0 with 1M hydrochloric acid, filter and sterilize with a cylindrical filter, pack in aliquots, and store in a refrigerator at 4°C....

Embodiment 2

[0037] Effects of GL-V9 combined with daunorubicin on U937 cell xenograft tumor in nude mice

[0038] 1. Test drugs

[0039] (1)GL-V9(C 24 h 27 o 5 N, molecular weight: 409.47) provided by China Pharmaceutical University, light yellow powder, purity greater than 99%, after jet milling, stored at room temperature. When administering, weigh the drug powder, suspend it with 0.5% CMC-Na solution, and administer it by intragastric administration at 0.2 mL / 20 g of body weight.

[0040] (2) Daunorubicin hydrochloride for injection was provided by Nanjing Drum Tower Hospital and kept away from light. Before use, make up the required concentration with normal saline, and inject it into the tail vein.

[0041] 2. Cell lines

[0042] Human AML cell line U937 was purchased from the Institute of Cells, Chinese Academy of Sciences, Shanghai. The cells used were cultured with RPMI1640 medium containing 100 U / mL penicillin, 100 mg / mL streptomycin and 10% fetal bovine serum.

[0043] 3...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses application of a flavonoid derivative GL-V9 and anthracycline antibiotics in preparation of a leukemia treatment medicine, and belongs to the technical field of medicines. It is found that the flavonoid derivative GL-V9 combined with low-dose anthracycline antibiotics can significantly inhibit growth of acute myelogenous leukemia (AML) cells, MTT experiments and U937 cell nude mouse transplantation tumor models verify that the GL-V9 and the low-dose anthracycline antibiotics can play a synergistic anti-AML effect, and the application potential of the combined administration mode in treatment of AML is prompted.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of GL-V9 and anthracycline antibiotics in the preparation of medicines for treating leukemia. Background technique [0002] Leukemia is a kind of malignant clonal disease of hematopoietic stem cells, commonly known as "blood cancer". Leukemic cells have the characteristics of uncontrolled proliferation, abnormal differentiation, and blocked apoptosis, so they can proliferate and accumulate in the bone marrow and other hematopoietic tissues without restriction, gradually replacing the normal hematopoietic function, making red blood cells, white blood cells, etc. unable to function normally. Produce and function, and infiltrate other non-hematopoietic tissues and organs, causing a series of symptoms, multiple organ failure, and even death. Leukemia patients may experience varying degrees of anemia, hemorrhage, enlarged liver, spleen, and lymph nodes, i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4025A61K31/704A61P35/02
CPCA61K31/4025A61K31/704A61P35/02A61K2300/00
Inventor 郭青龙惠慧李慧
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com